At bivariate analysis, niacin intake was lower in NAFLD subjects with steatosis ≥ 2 compared to those with low-grade or no steatosis (p < 0.05 at Wilcoxon, adj p = 0.02 vs steatosis < 2, Figure 1A) and in PNPLA3 CG/GG carriers (p < 0.05 at Wilcoxon, adj p = 0.02 vs PNPLA3 CC, Figure 1B). Here, PNPLA3 is linked to metabolic dysfunction-associated steatotic liver disease.